BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1364 related articles for article (PubMed ID: 26424865)

  • 21. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldan V; Vicente V; Valdés M; Marín F; Lip GYH
    Thromb Haemost; 2017 Oct; 117(10):1848-1858. PubMed ID: 28799620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Gao X; Cai X; Yang Y; Zhou Y; Zhu W
    Front Cardiovasc Med; 2021; 8():757087. PubMed ID: 34881309
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of bleeding risk-prediction scores in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Kiviniemi T; Puurunen M; Schlitt A; Rubboli A; Karjalainen P; Vikman S; Niemelä M; Lahtela H; Lip GY; Airaksinen KE
    Am J Cardiol; 2014 Jun; 113(12):1995-2001. PubMed ID: 24793675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the Appropriateness of Oral Anticoagulation for Atrial Fibrillation in Advanced Frailty: Use of Stroke and Bleeding Risk-Prediction Models.
    O'Caoimh R; Igras E; Ramesh A; Power B; O'Connor K; Liston R
    J Frailty Aging; 2017; 6(1):46-52. PubMed ID: 28244558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation.
    O'Brien EC; Holmes DN; Thomas LE; Fonarow GC; Allen LA; Gersh BJ; Kowey PR; Singer DE; Ezekowitz MD; Naccarelli GV; Ansell JE; Chan PS; Mahaffey KW; Go AS; Freeman JV; Reiffel JA; Peterson ED; Piccini JP; Hylek EM
    Circulation; 2018 Aug; 138(9):889-897. PubMed ID: 29678813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.
    Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Romiti GF; Marin F; Lip GYH
    J Am Heart Assoc; 2018 Sep; 7(18):e009766. PubMed ID: 30371183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
    Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
    J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incremental prognostic value of renal function for stroke prediction in atrial fibrillation.
    O'Brien EC; Holmes DN; Thomas L; Singer DE; Fonarow GC; Mahaffey KW; Kowey PR; Hylek EM; Pokorney SD; Ansell JE; Pencina MJ; Peterson ED; Piccini JP;
    Int J Cardiol; 2019 Jan; 274():152-157. PubMed ID: 30144994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry.
    Chichareon P; Winijkul A; Lip GYH; Krittayaphong R
    Br J Clin Pharmacol; 2023 Aug; 89(8):2472-2482. PubMed ID: 36942465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk scores for major bleeding from direct oral anticoagulants: comparing predictive performance in patients with atrial fibrillation.
    Campos-Staffico AM; Jacoby JP; Dorsch MP; Limdi NA; Barnes GD; Luzum JA
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102285. PubMed ID: 38292348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
    Lip GYH; Lane DA; Buller H; Apostolakis S
    Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry.
    Proietti M; Romiti GF; Vitolo M; Potpara TS; Boriani G; Lip GYH
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):778-786. PubMed ID: 34555148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
    Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
    Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.
    Aggarwal R; Ruff CT; Virdone S; Perreault S; Kakkar AK; Palazzolo MG; Dorais M; Kayani G; Singer DE; Secemsky E; Piccini J; Tahir UA; Shen C; Yeh RW
    Circulation; 2023 Sep; 148(12):936-946. PubMed ID: 37621213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.